Abstract
We present a rare case of dermatomyositis associated with nivolumab therapy for melanoma. Nivolumab is an immune checkpoint inhibitor that blocks the programmed death-1 (PD1) receptor and has a number of associated immunotherapy related adverse events. Although most are T-cell mediated, some are antibody mediated mimics of classical autoimmune diseases. We review the characteristics of other cases of anti-PD1 associated dermatomyositis and the recent literature to better understand how to classify and treat this challenging immunotherapy related adverse event.
Original language | English (US) |
---|---|
Article number | 4c21b068 |
Journal | Dermatology online journal |
Volume | 26 |
Issue number | 8 |
State | Published - Aug 2020 |
Externally published | Yes |
Keywords
- Dermatomyositis
- Immune checkpoint inhibitors
- Immunotherapy-related adverse events
- Melanoma
- Nivolumab
- PD 1
- PDL1
- Pembrolizumab
ASJC Scopus subject areas
- Dermatology